Takhzyro (lanadelumab)

pCPA File Number: 21175

Negotiation Status:

Concluded with an LOI

Indication(s):

Hereditary Angioedema

Sponsor/Manufacturer:

Shire Pharma Canada ULC

CDA-AMC Project Number:

SR0618-000

pCPA Engagement Letter Issued:

2020-02-21

Negotiation Process Concluded:

2020-10-30